Savara (NASDAQ:SVRA) Rating Lowered to Neutral at LADENBURG THALM/SH SH

Savara (NASDAQ:SVRA) was downgraded by research analysts at LADENBURG THALM/SH SH from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Thursday, The Fly reports.

Other equities analysts have also issued reports about the stock. Canaccord Genuity set a $22.00 price target on shares of Savara and gave the company a “buy” rating in a research report on Monday, March 25th. Zacks Investment Research upgraded shares of Savara from a “hold” rating to a “buy” rating and set a $10.00 price target on the stock in a research report on Thursday, April 11th. JMP Securities lowered shares of Savara from an “outperform” rating to a “market perform” rating in a research report on Thursday. BidaskClub upgraded shares of Savara from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 4th. Finally, Roth Capital set a $10.00 price target on shares of Savara and gave the company a “hold” rating in a research report on Tuesday, May 14th. Five research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $14.20.

NASDAQ:SVRA opened at $10.57 on Thursday. The stock has a market capitalization of $376.22 million, a price-to-earnings ratio of -8.19 and a beta of 0.95. Savara has a 12 month low of $6.21 and a 12 month high of $14.06. The company has a current ratio of 12.05, a quick ratio of 12.05 and a debt-to-equity ratio of 0.24.

Savara (NASDAQ:SVRA) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.34) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.39) by $0.05. Research analysts predict that Savara will post -1.63 earnings per share for the current fiscal year.

In other news, COO Jaakko Taneli Jouhikainen sold 7,815 shares of the company’s stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $9.00, for a total transaction of $70,335.00. Following the transaction, the chief operating officer now directly owns 184,754 shares in the company, valued at $1,662,786. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Richard J. Hawkins sold 25,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $11.10, for a total transaction of $277,500.00. Following the transaction, the director now owns 21,682 shares in the company, valued at $240,670.20. The disclosure for this sale can be found here. Insiders have sold 75,261 shares of company stock worth $744,174 over the last quarter. 6.50% of the stock is owned by company insiders.

Several hedge funds have recently made changes to their positions in SVRA. FMR LLC acquired a new position in shares of Savara during the fourth quarter worth approximately $2,830,000. Vanguard Group Inc. lifted its position in shares of Savara by 23.6% during the third quarter. Vanguard Group Inc. now owns 1,246,240 shares of the company’s stock worth $13,908,000 after purchasing an additional 238,358 shares in the last quarter. Morgan Stanley raised its stake in shares of Savara by 224.1% during the third quarter. Morgan Stanley now owns 205,560 shares of the company’s stock worth $2,294,000 after buying an additional 142,140 shares during the last quarter. Millennium Management LLC bought a new stake in shares of Savara during the fourth quarter worth approximately $714,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Savara during the first quarter worth approximately $466,000. Institutional investors own 45.71% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Featured Story: What does earnings per share mean?

The Fly

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.